RADical response puts an exceptional responder in CHKmate: A synthetic lethal curative response to DNA-Damaging chemotherapy?

Guang Peng, Scott E. Woodman, Gordon B. Mills

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome-based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.

Original languageEnglish (US)
Pages (from-to)988-990
Number of pages3
JournalCancer discovery
Volume4
Issue number9
DOIs
StatePublished - Sep 2014
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'RADical response puts an exceptional responder in CHKmate: A synthetic lethal curative response to DNA-Damaging chemotherapy?'. Together they form a unique fingerprint.

Cite this